Catherine Belle Meador, M.D.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Small Cell Lung Carcinoma | 8 | 2025 | 454 | 1.540 |
Why?
|
Lung Neoplasms | 21 | 2025 | 13594 | 1.380 |
Why?
|
Drug Resistance, Neoplasm | 11 | 2024 | 5342 | 0.920 |
Why?
|
Thoracic Neoplasms | 1 | 2023 | 269 | 0.700 |
Why?
|
Carcinoma, Non-Small-Cell Lung | 5 | 2023 | 5434 | 0.680 |
Why?
|
Central Nervous System | 1 | 2025 | 1346 | 0.570 |
Why?
|
Leadership | 2 | 2016 | 1396 | 0.540 |
Why?
|
Piperazines | 2 | 2025 | 2553 | 0.520 |
Why?
|
Molecular Targeted Therapy | 3 | 2020 | 2830 | 0.490 |
Why?
|
Genotype | 3 | 2021 | 13048 | 0.490 |
Why?
|
Protein Kinase Inhibitors | 6 | 2021 | 5707 | 0.490 |
Why?
|
Antineoplastic Agents | 6 | 2021 | 13698 | 0.440 |
Why?
|
Mutation | 12 | 2024 | 30266 | 0.350 |
Why?
|
Biomedical Research | 2 | 2016 | 3463 | 0.350 |
Why?
|
MAP Kinase Signaling System | 2 | 2015 | 1495 | 0.310 |
Why?
|
Proto-Oncogene Proteins B-raf | 2 | 2015 | 2059 | 0.300 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 4 | 2025 | 11886 | 0.290 |
Why?
|
Acrylamides | 3 | 2017 | 261 | 0.240 |
Why?
|
Neoplasms | 4 | 2023 | 22389 | 0.240 |
Why?
|
Negotiating | 2 | 2016 | 152 | 0.230 |
Why?
|
Education, Medical, Graduate | 1 | 2016 | 2422 | 0.220 |
Why?
|
Education, Medical | 1 | 2016 | 1742 | 0.220 |
Why?
|
Exodeoxyribonucleases | 1 | 2024 | 191 | 0.210 |
Why?
|
Phthalazines | 1 | 2025 | 397 | 0.200 |
Why?
|
Epigenomics | 2 | 2024 | 961 | 0.190 |
Why?
|
Aniline Compounds | 3 | 2017 | 1095 | 0.180 |
Why?
|
Career Choice | 2 | 2016 | 769 | 0.170 |
Why?
|
Biology | 1 | 2021 | 292 | 0.160 |
Why?
|
Paraneoplastic Syndromes, Nervous System | 1 | 2019 | 24 | 0.160 |
Why?
|
Gene Amplification | 1 | 2024 | 1099 | 0.160 |
Why?
|
Genetic Variation | 1 | 2014 | 6611 | 0.160 |
Why?
|
Quinazolines | 2 | 2015 | 1373 | 0.150 |
Why?
|
Tumor Microenvironment | 3 | 2024 | 3952 | 0.150 |
Why?
|
Cardiology Service, Hospital | 1 | 2019 | 242 | 0.150 |
Why?
|
Mice, Nude | 4 | 2017 | 3631 | 0.140 |
Why?
|
Focal Adhesion Protein-Tyrosine Kinases | 1 | 2017 | 185 | 0.130 |
Why?
|
Receptor, EphA2 | 1 | 2016 | 41 | 0.130 |
Why?
|
Phosphoproteins | 1 | 2024 | 2452 | 0.120 |
Why?
|
Exons | 1 | 2021 | 2395 | 0.120 |
Why?
|
Humans | 27 | 2025 | 768970 | 0.120 |
Why?
|
Colorectal Neoplasms | 1 | 2015 | 6982 | 0.120 |
Why?
|
Group Processes | 1 | 2016 | 228 | 0.120 |
Why?
|
src-Family Kinases | 1 | 2017 | 539 | 0.120 |
Why?
|
Neoplasm Recurrence, Local | 3 | 2025 | 9442 | 0.110 |
Why?
|
Cell Line, Tumor | 7 | 2024 | 17173 | 0.110 |
Why?
|
Niacinamide | 1 | 2016 | 418 | 0.110 |
Why?
|
Lymphocytes, Tumor-Infiltrating | 1 | 2019 | 1105 | 0.110 |
Why?
|
Professional Competence | 1 | 2016 | 430 | 0.100 |
Why?
|
Curriculum | 2 | 2016 | 3782 | 0.100 |
Why?
|
INDEL Mutation | 1 | 2013 | 267 | 0.100 |
Why?
|
Patient Admission | 1 | 2019 | 1370 | 0.100 |
Why?
|
Cell Lineage | 1 | 2020 | 2576 | 0.090 |
Why?
|
Cell Transformation, Neoplastic | 2 | 2024 | 2848 | 0.090 |
Why?
|
Benzamides | 1 | 2016 | 1387 | 0.090 |
Why?
|
DNA, Neoplasm | 1 | 2015 | 1748 | 0.080 |
Why?
|
Xenograft Model Antitumor Assays | 3 | 2024 | 3621 | 0.080 |
Why?
|
Animals | 11 | 2024 | 169335 | 0.080 |
Why?
|
Academic Medical Centers | 1 | 2019 | 2784 | 0.080 |
Why?
|
Treatment Outcome | 4 | 2025 | 65480 | 0.080 |
Why?
|
Receptor Protein-Tyrosine Kinases | 1 | 2014 | 1629 | 0.070 |
Why?
|
Protein-Tyrosine Kinases | 1 | 2015 | 2433 | 0.070 |
Why?
|
Sensitivity and Specificity | 1 | 2021 | 14752 | 0.060 |
Why?
|
Genome, Human | 2 | 2015 | 4456 | 0.060 |
Why?
|
Octamer Transcription Factors | 1 | 2023 | 18 | 0.060 |
Why?
|
Healthcare Disparities | 1 | 2019 | 3421 | 0.060 |
Why?
|
Aged, 80 and over | 3 | 2025 | 59739 | 0.050 |
Why?
|
Mice | 8 | 2024 | 82072 | 0.050 |
Why?
|
Biopsy | 1 | 2015 | 6805 | 0.050 |
Why?
|
Lactates | 1 | 2023 | 401 | 0.050 |
Why?
|
Cell Proliferation | 2 | 2016 | 10486 | 0.050 |
Why?
|
Health Services Accessibility | 1 | 2019 | 5522 | 0.050 |
Why?
|
Aged | 5 | 2025 | 171786 | 0.050 |
Why?
|
Genetic Testing | 1 | 2014 | 3591 | 0.040 |
Why?
|
Chemokines | 1 | 2024 | 963 | 0.040 |
Why?
|
Proto-Oncogene Proteins c-myc | 1 | 2024 | 998 | 0.040 |
Why?
|
Male | 6 | 2025 | 365203 | 0.040 |
Why?
|
Genomics | 1 | 2014 | 5928 | 0.040 |
Why?
|
Adenocarcinoma | 1 | 2015 | 6401 | 0.040 |
Why?
|
Gene Expression Regulation, Neoplastic | 2 | 2024 | 8664 | 0.040 |
Why?
|
Basic Helix-Loop-Helix Transcription Factors | 1 | 2023 | 1143 | 0.040 |
Why?
|
Pneumonectomy | 1 | 2023 | 1159 | 0.030 |
Why?
|
Middle Aged | 4 | 2025 | 223737 | 0.030 |
Why?
|
Melanoma | 1 | 2014 | 5709 | 0.030 |
Why?
|
Heart Failure | 1 | 2019 | 11879 | 0.030 |
Why?
|
Female | 6 | 2025 | 397515 | 0.030 |
Why?
|
Chemotherapy, Adjuvant | 1 | 2023 | 3554 | 0.030 |
Why?
|
Survival Rate | 2 | 2019 | 12873 | 0.030 |
Why?
|
Drug Screening Assays, Antitumor | 1 | 2015 | 719 | 0.030 |
Why?
|
Immunity, Innate | 1 | 2024 | 3080 | 0.020 |
Why?
|
Adult | 2 | 2025 | 223851 | 0.020 |
Why?
|
Drug Synergism | 1 | 2016 | 1762 | 0.020 |
Why?
|
Combined Modality Therapy | 1 | 2023 | 8559 | 0.020 |
Why?
|
Epigenesis, Genetic | 1 | 2024 | 3836 | 0.020 |
Why?
|
Drug Evaluation, Preclinical | 1 | 2015 | 1340 | 0.020 |
Why?
|
CD8-Positive T-Lymphocytes | 1 | 2024 | 4651 | 0.020 |
Why?
|
DNA Methylation | 1 | 2024 | 4432 | 0.020 |
Why?
|
ras Proteins | 1 | 2015 | 1058 | 0.020 |
Why?
|
Benzimidazoles | 1 | 2015 | 864 | 0.020 |
Why?
|
Transfection | 1 | 2017 | 5763 | 0.020 |
Why?
|
Signal Transduction | 3 | 2017 | 23653 | 0.020 |
Why?
|
Neoplasm Staging | 1 | 2023 | 11262 | 0.020 |
Why?
|
Macrophages | 1 | 2023 | 5801 | 0.020 |
Why?
|
Immunotherapy | 1 | 2024 | 4756 | 0.020 |
Why?
|
Inpatients | 1 | 2019 | 2569 | 0.020 |
Why?
|
Health Status Disparities | 1 | 2019 | 1886 | 0.020 |
Why?
|
Retrospective Studies | 3 | 2023 | 81903 | 0.020 |
Why?
|
Proto-Oncogene Proteins p21(ras) | 1 | 2015 | 1769 | 0.020 |
Why?
|
Boston | 1 | 2019 | 9377 | 0.020 |
Why?
|
Drug Therapy, Combination | 1 | 2015 | 6320 | 0.020 |
Why?
|
Patient Readmission | 1 | 2019 | 3313 | 0.020 |
Why?
|
Lung | 1 | 2023 | 10099 | 0.010 |
Why?
|
DNA Copy Number Variations | 1 | 2013 | 2055 | 0.010 |
Why?
|
Transcription Factors | 1 | 2023 | 12174 | 0.010 |
Why?
|
Sequence Analysis, DNA | 1 | 2013 | 4785 | 0.010 |
Why?
|
Longitudinal Studies | 1 | 2017 | 14794 | 0.010 |
Why?
|
High-Throughput Nucleotide Sequencing | 1 | 2013 | 3671 | 0.010 |
Why?
|
Apoptosis | 1 | 2016 | 9527 | 0.010 |
Why?
|
Prognosis | 1 | 2019 | 30046 | 0.010 |
Why?
|
Risk Assessment | 1 | 2019 | 24333 | 0.010 |
Why?
|
Time Factors | 1 | 2019 | 40261 | 0.010 |
Why?
|
Follow-Up Studies | 1 | 2017 | 39394 | 0.010 |
Why?
|
Polymorphism, Single Nucleotide | 1 | 2013 | 16053 | 0.010 |
Why?
|
Prospective Studies | 1 | 2017 | 54962 | 0.010 |
Why?
|
Risk Factors | 1 | 2019 | 74976 | 0.010 |
Why?
|